Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders and director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the potential future utility of isatuximab-irfc (Sarclisa) in multiple myeloma.
On March 31, 2021, the FDA approved isatuximab in combination with carfilzomib (Kyprolis) and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.
The approval will likely increase the utility of isatuximab in the community setting, says Usmani. Many providers and patients may prefer the less frequent dosing regimen of isatuximab/carfilzomib/dexamethasone compared with other standard options available during the first year of treatment, Usmani explains.
Moreover, isatuximab and carfilzomib are given intravenously, which could be advantageous for some patients vs daratumumab (Darzalex)-based treatment, Usmani says. Additionally, patients who received daratumumab in the frontline setting could receive isatuximab as subsequent therapy, Usmani says.
Based on several ongoing, early phase clinical trials, it is likely that novel isatuximab-based combinations will emerge in the frontline setting for patients with multiple myeloma, concludes Usmani.